THE MANUFACTURING IMPERATIVE

Biomanufacturing is converging on a common requirement: greater productivity with more control. In monoclonal-antibody and cell-culture vaccine processes, that means intensified, serum-free platforms that boost yield and ensure supply chain security. In cell and gene therapy, it means retaining phenotype, vector quality and process consistency as technologies under development are being scaled and transferred. Across modalities, well-characterised and high-quality raw materials are moving from an operational preference to a strategic must-have.

THE REGULATORY LANDSCAPE

This evolution aligns with convergent global expectations. FDA’s 2024 draft CGT guidance highlights adventitious-agent risk, lot-to-lot consistency, identity and material qualification; it advises manufacturers to consider materials free of human- or animal-derived proteins, such as recombinant proteins. EMA states that, when applicable, animal reagents should be avoided and replaced with non-animal-derived reagents of defined composition. ICH Q5A(R2) likewise advises avoiding human- and animal-derived raw materials, including serum and porcine trypsin, whenever possible. In Japan, PMDA expects qualification and specifications for media, additives and reagents and advises avoiding heterogeneous serum wherever possible. In China, NMPA has made ICH Q5D – derivation and characterisation of cell substrates, applicable to relevant studies. Overall, the pattern is global, and the aim is for GMP manufacturers to have risk-based CMC strategies for their processes through defined composition, lot-to-lot consistency, traceability, regulatory-aligned documentation and supply chain security.